Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: kiwi who wrote (1203)	6/9/1998 7:49:00 AM
From: James Marks	Read Replies (1) \| Respond to of 2887

I am not sure I understand why some of you nay slayers keep jumping all over Jeff Henken. He has done nothing wrong! Frankly he has worked his butt off to inform all of those interested in the stocks in which involved. He does this so others can join us if they choose! He does it not for personal gain,unlike others that pump and dump. He buys and everyone can get in at the same time and out when they so choose.Frankly, any of the shareholders that are long abmi could have made a tremendous profit from 40 cents to a dollar but the majority did not sell.We didn't because we believe in the longer term picture and know that there is more value in the stock. Had Dr Summers nay slayers not showed up I am sure we would be sitting at over 1.00 now. I still can not figure out if your not long the stock why are you here! NorthStar I sure can not figure you out if your long this stock and posting all the negatives please be kind enough to let me know what other stock you have so I can short before you start your kill campaign. Lets get back to the positive and drop the personal attacks on Jeff and work at telling others what a good buy this Co is at this level.

To: kiwi who wrote (1203)	6/9/1998 9:48:00 AM
From: M.S.H	Read Replies (2) \| Respond to of 2887

They do have a problem with their line of credit. My gut feeling is they do not have it yet. I think Jeff is the one attacking everyone that tells the truth about ABMI. I can't say for sure that the things NORTHSTAR are saying are true. But, everything Dollarone has said is true. Dollarone just talked about things that are very easy to check into. Please just look at the filings and speak to Rash. I am not as diplomatic as Dollarone is, but I know what I am saying is true as well. Jeff, you are not giving facts, you are only speculating on the future and trusting the selective information that Rash is releasing to you. Of course you want to believe because you have 95,000 reasons to and everyone else that is long wants to believe. I don't even know what or who Tokyo Mex is, but I do like Mexican food, eventhough my wife will not let me eat as manny tortilla chips as I would like to. I am only telling the truth like it or not.

To: kiwi who wrote (1203)	6/9/1998 10:26:00 AM
From: Jeffrey L. Henken	Respond to of 2887

No kiwi I don't think there is any problem with the company's line of credit. They have already borrowed the first $600,000 and could be negotiating for more money as I write this for all we know. Unfortunately the thing about this line of credit is that the terms are much better for us and American BioMed when the stock price is higher. There are lots of reasons why a person like MSH might be here trying to make this deal sound like it has gone sour but in truth the burden of proof is on him and not American BioMed. No offense kiwi because I do actually know who you are but whatever game the three people attacking ABMI are playing it's their credibility that lacks believability and not American BioMeds. Lets look at the terms of the $5 million line of credit one more time and hopefully put it to bed: biz.yahoo.com American Biomed Inc. Receives A $5 Million Equity Line of Credit THE WOODLANDS, Texas--(BW HealthWire)--May 7, 1998--American BioMed Inc. (OTC Bulletin Board: ABMI - news), Thursday announced that the company has signed an agreement with an institutional investor that allows for American Biomed Inc. to receive up to five million dollars in an equity line of credit. According to American BioMed Inc.'s President and Chief Executive Officer Steven B. Rash, the company received $600,000 immediately upon the signing of the contract and has the ability to draw down additional funds against the remaining $5 million equity credit line at 30-day intervals if needed, over a two-year period, subject to meeting certain conditions prior to request for funding. The equity will be in the form of convertible preferred stock at a stated discount from the market price calculated at the time of conversion and carries an 8% dividend payable in cash or stock at the company's option. Rash stated: ''This transaction marks an important event in the company's history, in that we can now focus on taking our technology onto the commercialization phase. ''The company intends to use the funding in four principal areas. To actively market our existing 100%-silicon balloon catheter line of which we have 10 FDA approved products; secondly to accelerate the development of the company's guideware micro-filter technology; thirdly to expand the OmniCath(R) clinical trials from the on-going peripheral trials into the AV Fistula trials, and lastly, to continue discussions with strategic partners that can assist in commercially advancing our technologies.'' American BioMed utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease. The company's products include 100%-silicone-based catheters, through its Cathlab subsidiary; the Evert-O-Cath(TM), a toposcopic catheter for site-specific drug delivery and fluid removal; the OmniCath, an atherectomy catheter designed to remove athersclerotic plaque from obstructed blood vessels throughout the body; and the OmniFilter, which is used to prevent blood clots from reaching various organs of the body. The company has over 25 patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be an over $10 billion industry. ''Safe Harbor'' statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in the release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, the results of financing efforts, the effect of the company's accounting policies, and other risks detailed in the company's Securities and Exchange Commission filings. Contact: American BioMed Inc. Steven B. Rash, 281/367-3895 or Coffin Communications Matt Lepo, (Investor Relations) 818/789-0100 or Coffin/Mottola Communications Christi Mottola, (Press Relations) 714/851-1109